A global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

WEBSITE
FY 2023 SALES BY THERAPEUTIC AREA AND MEDICINE (€M)
(GROWTH AT CONSTANT EXCHANGE RATES)

**Oncology**
- Somatuline 1,065 | -10.4%
- Decapeptyl 546 | 5.9%
- Cabometyx 535 | 22.9%
- Onivyde 164 | 17.3%
- Tazverik 38 | n/a
- Other Oncology 4 | -49.4%

**Rare Disease**
- Rare Disease 117

**Neuroscience**
- Dysport 649 | 14.3%
- Other Neuroscience 11 | 20.2%

**TOTAL-SALES GROWTH +6.7%**

TOTAL SALES² (€M) (GROWTH RATES AT CONSTANT EXCHANGE RATES)

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2,643</td>
<td>+12.7%</td>
</tr>
<tr>
<td>2022</td>
<td>3,025</td>
<td>+8.5%</td>
</tr>
<tr>
<td>2023</td>
<td>3,128</td>
<td>+6.7%</td>
</tr>
</tbody>
</table>

GEOGRAPHIC BREAKDOWN:
TOTAL SALES BY REGION: 2023

- 33% North America
- 40% Europe
- 27% Rest of World

In this map, Europe is defined as the E.U., the UK, Iceland, Liechtenstein, Norway and Switzerland.

FOCUS OF GENERATION IPSEN

**ENVIRONMENT**
- Science-based GHG-emission reductions: Scope 1, 2 & 3
- Net zero by 2045

**PATIENTS**
- Reduce time to make non-FDA/EMA regulatory submissions by 25%

**PEOPLE**
- Gender balance in Global Leadership Team
- Increase proportion of colleagues engaged in healthcare or environmental projects to 35% by 2024

**GOVERNANCE**
- ISO 37001 certification for anti-corruption management systems

¹ Growth incorporates North America only; excludes sales to ex-U.S. partner.
² Excludes sales from Consumer HealthCare, divested in 2022.